IDBS Adds Synthetic Chemistry to Its Cloud-Based R&D Platform
The latest addition to the company’s cloud-based R&D platform provides organic chemists with the capability to transfer all experimental data to an on-premise site or cloud environment.
IDBS, a provider of advanced software for R&D organizations, has included a synthetic chemistry offering that extends its E-WorkBook Connect cloud-based platform, part of the company’s E-WorkBook Cloud, an R&D cloud platform that supports internal, external, and hybrid data management and research needs.
Contract research organizations (CROs) involved in medicinal chemistry and scale-up chemical intermediates face significant security, communication, and collaboration challenges with current existing tools. With the now-extended E-WorkBook Connect, organic chemists can share data externally and collaborate with partners using a secure work space. It also provides chemists with the uncommon ability to transfer all experimental data to an on-premise or hosted E-WorkBook environment.
While some CROs are allowed direct access to a secure corporate electronic laboratory notebook (ELN), others are mandated to maintain a local installation of the desktop ELN. Both approaches are an additional overhead that IDBS’ E-WorkBook Connect platform resolves, according to the company.
“Extending the capabilities of E-WorkBook Connect with stoichiometry, to support synthetic organic chemistry, addresses the data management challenges and costs associated with collaborative research, especially when it comes to communication,” said Ian Peirson, head of product planning at IDBS, in a company press release.
“The advantages are clear: with our technology, a simple email invitation process sets up a secure workspace with a collaborator, and this then enables both sides to view progress, and complete the transfer of all information and metadata to supplement the internal corporate knowledge base,” he added.
Source: IDBS
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
